Latest Content

Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

April 15th 2025, 9:00pm

By Ashley Chan

Article

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.

Understanding How to Advance Immunotherapy Strategy Models in Melanoma

April 15th 2025, 8:00pm

By Dr. Georgina Long

Video

Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.

Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC

April 15th 2025, 7:00pm

By Jax DiEugenio

Article

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.

Spring Looks Different This Year

April 15th 2025, 5:00pm

By Georgia Hurst

Article

What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich

First Patient Treated in Trial of PHST001 for Advanced Solid Tumors

April 15th 2025, 4:00pm

By Spencer Feldman

Article

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas

April 15th 2025, 3:00pm

By Alex Biese

Article

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

Nubeqa Combo Improves Outcomes in Metastatic Prostate Cancer

April 15th 2025, 1:00pm

By Kristi Rosa

Article

Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.

Expanding Definition of Cancer Survivorship Highlights Need for New Standards

April 14th 2025, 9:00pm

By Kristie L. Kahl

Article

Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.

Radiation Therapy Advances Improve Quality of Life for GI Cancer

April 14th 2025, 8:00pm

By Dr. Rachit Kumar

Video

Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve quality of life for GI cancer.

FDA Approves Cabometyx, Another Treatment for Neuroendocrine Tumors

April 14th 2025, 7:00pm

By Alex Biese

Article

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Springtime Health After My Testicular Cancer Diagnosis

April 14th 2025, 5:00pm

By Brian Sluga

Article

Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing change and well-being.

AU-007 Combo Dosing Begins in Melanoma Phase 2 Trial With Opdivo

April 14th 2025, 4:00pm

By Spencer Feldman

Article

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.

Trial of SVV-001, Opdivo and Yervoy in Neuroendocrine Tumors Launching

April 14th 2025, 3:00pm

By Alex Biese

Article

A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.

Early Detection Critical for Testicular Cancer in Young Men

April 14th 2025, 1:02pm

By Dr. Benjamin Garmez

Video

April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 years old.

Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML

April 13th 2025, 6:00pm

By Alex Biese

Article

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.